Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3
A Systematic Review and Meta-analysis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 22, 2022
- Accepted in final form August 2, 2022
- First Published October 12, 2022.
Author Disclosures
- Dalia Rotstein, MD, MPH,
- Jacqueline M. Solomon, MD,
- Maria Pia Sormani, PhD,
- Xavier Montalban, MD, PhD,
- Xiang Y. Ye, MSc,
- Dina Dababneh, MD,
- Alexandra Muccilli, MD,
- Georges Saab, MD and
- Prakesh Shah, MD, MSc
- Dalia Rotstein, MD, MPH,
(1) Biogen (2) Sanofi Aventis (3) EMD Serono (4) Alexion (5) Roche (6) Novartis
NONE
(1) Sanofi Aventis (2) Roche (3) Novartis (4) EMD Serono (5) Alexion (6) Biogen
Frontiers in Neurology, Associate Editor, 2019-2022
NONE
NONE
NONE
(1) Sanofi Aventis (2) Roche (3) Alexion (4) Biogen (5) EMD Serono (6) Novartis
(1) Alexion (2) Biogen (3) EMD Serono (4) Novartis (5) Roche (6) Sanofi Aventis
NONE
NONE
I have received research support from Roche.
NONE
University of Toronto Division of Neurology
I have received research support from the MS Society of Canada and the Consortium for Multiple Sclerosis Centers (CMSC).
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline M. Solomon, MD,
None
NONE
I have received speaker or consultant fees from Alexion, Biogen, and EMD Serono.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Pia Sormani, PhD,
Medday, Merck, Sanofi, Roche, Novartis, GeNeuro, Biogen, Celgene, Immunic
NONE
Merck, Sanofi, Novartis, Biogen, Roche
NONE
NONE
NONE
NONE
Merck, Biogen, Sanofi, Roche, Novartis, GeNeuro, Immunic, Celgene
NONE
NONE
NONE
Biogen, Roche, Merck, Novartis
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Montalban, MD, PhD,
(1) Actelion, (2) Alexion, (3) Biogen, (4) Bristol-Myers Squibb/Celgene, (5) EMD Serono, (6) Genzyme, (7) Hoffmann-La Roche, (8) Immunic, (9) Janssen Pharmaceuticals, (10) Medday, (11) Merck, (12) Mylan, (13) Nervgen, (14) Novartis, (15) Sanofi-Genzyme, (16) Teva Pharmaceutical, (17) TG Therapeutics
NONE
Travel to scientific meetings: (1) Actelion, (2) Alexion, (3) Biogen, (4) Bristol-Myers Squibb/Celgene, (5) EMD Serono, (6) Genzyme, (7) Hoffmann-La Roche, (8) Immunic, (9) Janssen Pharmaceuticals, (10) Medday, (11) Merck, (12) Mylan, (13) Nervgen, (14) Novartis, (15) Sanofi-Genzyme, (16) Teva Pharmaceutical, (17) TG Therapeutics, (18) Excemed, (19) MSIF and (20) NMSS.
Member of editorial boards: (1) Multiple Sclerosis Journal, (2) Journal of Neurology, (3) The International MS Journal, (4) Revista de Neurologia, (5) Therapeutic Advances in Neurological Disorders
NONE
NONE
NONE
(1) Biogen, (2) Celgene, (3) Merck, (4) Novartis, (5) Roche, (6) Sanofi-Genzyme and (7) Teva Pharmaceutical.
NONE
NONE
NONE
NONE
NONE
NONE
(1) Vice-president, Multiple Sclerosis Foundation of Barcelona (FEM) and (2) President, Fundació Cemcat
NONE
NONE
NONE
NONE
NONE
NONE
- Xiang Y. Ye, MSc,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Dina Dababneh, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Alexandra Muccilli, MD,
None
NONE
Commercial entity - Biogen speaking engagement for MS nurses, cheque.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Georges Saab, MD and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Prakesh Shah, MD, MSc
None
NONE
None
Acta Obstetricia Gynecologica Scandinavica- editorial advisory board member 2013 onwards.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Medicine, (D.R., A.M., G.S.), University of Toronto, Ontario, Canada; St. Michael's Hospital (D.R., A.M., G.S.), Toronto, Ontario, Canada; Department of Medicine, (J.M.S.), McMaster University, Hamilton, Ontario, Canada; Department of Health Sciences (M.P.S.), Section of Biostatistics, University of Genova, Italy; IRCCS Ospedale Policlinico San Martino (M.P.S.), Genova, Italy; Department of Neurology and Cemcat (X.M.), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona; Department of Pediatrics (X.Y.Y., P.S.), Mount Sinai Hospital, Toronto, Canada; Columbia University Irving Medical Center (D.D.), Department of Neurology, New York City; York Presbyterian Hospital (NYP) (D.D.), New York City; and Institute of Health (P.S.), Policy, Management and Evaluation, University of Toronto, Canada.
- Correspondence
Dr. Rotstein dalia.rotstein{at}unityhealth.to
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.